Inclusion Criteria:

          -  Stage IIIB or IV NSCLC (any histology) at the time of study entry

          -  Histologically or cytologically confirmed diagnosis of NSCLC that is:

               1. EGFR wt as per patient standard of care by a validated test

               2. AND ALK-negative rearrangement as part of the patient standard of care by a
                  validated test

               3. AND (by central assessment) either:

                    -  Cohort 1: Pre-treated patients with cMET GCN ≥ 6 or

                    -  Cohort 2: Pre-treated patients with cMET GCN ≥4 and < 6, or

                    -  Cohort 3: Pre-treated patients with cMET GCN < 4, or

                    -  Cohort 4: Pre-treated patients with cMET mutations regardless of cMET GCN,
                       or

                    -  Cohort 5: Treatment-naïve patients with cMET dysregulation, or

                    -  Cohort 6: Pre-treated patients with either cMET GCN ≥ 10 without cMET
                       mutations or cMET mutations regardless of cMET GCN, or

                    -  Cohort 7: Treatment-naïve patients with cMET mutations regardless of cMET
                       GCN

          -  To be eligible for Cohorts 1-4, patients must have failed one or two prior lines of
             systemic therapy for advanced/metastatic disease

          -  To be eligible for Cohort 6, patients must have failed one prior line of systemic
             therapy for advanced/metastatic disease

          -  To be eligible for Cohort 5 and Cohort 7, patients must not have received any systemic
             therapy for advanced/metastatic disease

          -  At least one measurable lesion as defined by RECIST 1.1

          -  Patients must have recovered from all toxicities related to prior anticancer therapies
             to grade ≤ 1 (CTCAE v 4.03). Patients with any grade of alopecia are allowed to enter
             the study.

          -  Patients must have adequate organ function

          -  ECOG performance status (PS) of 0 or 1 Details and other protocol-defined inclusion
             criteria may apply

        Exclusion Criteria:

          -  Prior treatment with crizotinib, or any other cMET or HGF inhibitor

          -  Patients with characterized EGFR mutations that predict sensitivity to EGFR therapy,
             including, but not limited to exon 19 deletions and exon 21 mutations

          -  Patients with characterized ALK-positive rearrangement

          -  Clinically significant, uncontrolled heart diseases.

          -  Patients receiving treatment with medications that cannot be discontinued at least 1
             week prior to first INC280 treatment and for the duration of the study:

               -  Strong inducers of CYP3A4

          -  Impairment of GI function or GI disease that may significantly alter the absorption of
             INC280

          -  Patients receiving treatment with any enzyme-inducing anticonvulsant

          -  Applicable to Cohorts 1-4 and Cohort 6 only: Previous anti-cancer and investigational
             agents within 4 weeks or ≤ 5 x half-life of the agent (whichever is longer) before
             first dose

          -  Pregnant or nursing women

          -  Women of child-bearing potential, unless they are using highly effective methods of
             contraception

          -  Sexually active males unless they use a condom during intercourse

          -  Presence or history of interstitial lung disease or interstitial pneumonitis,
             including clinically significant radiation pneumonitis

        Other protocol-defined exclusion criteria may apply